Therapeutics Md, Inc. TXMD
We take great care to ensure that the data presented and summarized in this overview for TherapeuticsMD, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in TXMD
Top Purchases
Top Sells
About TXMD
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Insider Transactions at TXMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 22
2024
|
Cooper C. Collins |
BUY
Open market or private purchase
|
Direct |
4,094
+7.3%
|
$4,094
$1.73 P/Share
|
|
Aug 21
2024
|
Cooper C. Collins |
BUY
Open market or private purchase
|
Direct |
1,200
+2.44%
|
$1,200
$1.7 P/Share
|
|
Dec 07
2023
|
Marlan D Walker Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,550
-6.78%
|
$9,100
$2.24 P/Share
|
|
Dec 06
2023
|
Marlan D Walker Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,500
-17.77%
|
$29,000
$2.31 P/Share
|
|
Dec 05
2023
|
Marlan D Walker Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
70,000
+46.17%
|
-
|
|
Nov 15
2023
|
Rubric Capital Management LP Director |
BUY
Grant, award, or other acquisition
|
Indirect |
877,192
+22.94%
|
$1,754,384
$2.28 P/Share
|
|
Aug 17
2023
|
Joseph Ziegler Principal Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+50.0%
|
-
|
|
Jun 28
2023
|
Rubric Capital Management LP Director |
BUY
Grant, award, or other acquisition
|
Indirect |
312,525
+13.12%
|
$937,575
$3.68 P/Share
|
|
Apr 12
2023
|
Marlan D Walker Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,170
-8.68%
|
$3,510
$3.65 P/Share
|
|
Apr 12
2023
|
Marlan D Walker Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,508
+14.66%
|
-
|
|
Apr 12
2023
|
Michael C Donegan Prin. Fin. and Acctg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+44.7%
|
-
|
|
Jan 27
2023
|
Michael C Donegan Prin. Fin. and Acctg. Officer |
SELL
Open market or private sale
|
Direct |
49
-0.41%
|
$245
$5.09 P/Share
|
|
Jan 26
2023
|
Michael C Donegan Prin. Fin. and Acctg. Officer |
SELL
Open market or private sale
|
Direct |
1,648
-12.16%
|
$8,240
$5.08 P/Share
|
|
Jan 26
2023
|
Michael C Donegan Prin. Fin. and Acctg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,940
+14.43%
|
-
|
|
Jan 24
2023
|
Michael C Donegan Prin. Fin. and Acctg. Officer |
SELL
Open market or private sale
|
Direct |
7
-0.09%
|
$35
$5.31 P/Share
|
|
Jan 23
2023
|
Michael C Donegan Prin. Fin. and Acctg. Officer |
SELL
Open market or private sale
|
Direct |
1,302
-14.6%
|
$6,510
$5.34 P/Share
|
|
Jan 23
2023
|
Michael C Donegan Prin. Fin. and Acctg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,365
+12.7%
|
-
|
|
Dec 30
2022
|
Rubric Capital Management LP Director |
SELL
Open market or private sale
|
Indirect |
29,000
-100.0%
|
$38,657,000
$1333.0 P/Share
|
|
Dec 09
2022
|
Rubric Capital Management LP Director |
BUY
Open market or private purchase
|
Indirect |
14,825
+0.84%
|
$88,950
$6.09 P/Share
|
|
Dec 09
2022
|
Brian Bernick Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
320
-7.63%
|
$1,920
$6.31 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 5.29K shares |
|---|---|
| Exercise of conversion of derivative security | 70K shares |
| Open market or private sale | 19.1K shares |
|---|